Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Best Buy warns of continued pressure on consumers

(Sharecast News) - Retailer Best Buy traded lower in pre-market after its warning that continued pressure on consumers was expected to hurt sales saw investors ignore Q4 revenues that came in ahead of expectations. Best Buy said Q4 revenues had fallen from $14.64bn to $13.94bn, ahead of expectations for a bigger drop to $13.68bn, while same-store sales rose 0.5% when analysts were expecting to see a 1.5% year-on-year decline.

Net income fell from $460.0m to $117.0m in Q4, principally due to a $2.02 per share impairment charge to Best Buy Health as a result of downward revisions in the unit's long-term financial projections. Domestic revenue fell to $12.72bn, down from $13.41bn a year earlier, while international revenue slipped to $1.23bn from $1.24bn.

As far as the new year was concerned, Best Buy expects same-store sales to be slightly lower year-on-year and below the mid-point of consensus estimates for an increase 1.5% as it warned shoppers will likely remain constrained by inflation in 2025.

As of 1310 GMT, Best Buy shares were down 0.85% in pre-market trading at $86.00 each.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.